JP2025509824A5 - - Google Patents

Info

Publication number
JP2025509824A5
JP2025509824A5 JP2024555332A JP2024555332A JP2025509824A5 JP 2025509824 A5 JP2025509824 A5 JP 2025509824A5 JP 2024555332 A JP2024555332 A JP 2024555332A JP 2024555332 A JP2024555332 A JP 2024555332A JP 2025509824 A5 JP2025509824 A5 JP 2025509824A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
bispecific antibody
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024555332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509824A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/064728 external-priority patent/WO2023178357A1/en
Publication of JP2025509824A publication Critical patent/JP2025509824A/ja
Publication of JP2025509824A5 publication Critical patent/JP2025509824A5/ja
Pending legal-status Critical Current

Links

JP2024555332A 2022-03-18 2023-03-20 二特異性抗体融合分子及びその使用方法 Pending JP2025509824A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263321563P 2022-03-18 2022-03-18
US63/321,563 2022-03-18
US202263330250P 2022-04-12 2022-04-12
US63/330,250 2022-04-12
US202263368852P 2022-07-19 2022-07-19
US63/368,852 2022-07-19
PCT/US2023/064728 WO2023178357A1 (en) 2022-03-18 2023-03-20 Bispecific antibody fusion molecules and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2025509824A JP2025509824A (ja) 2025-04-11
JP2025509824A5 true JP2025509824A5 (https=) 2026-03-27

Family

ID=86052253

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024555332A Pending JP2025509824A (ja) 2022-03-18 2023-03-20 二特異性抗体融合分子及びその使用方法

Country Status (9)

Country Link
US (1) US20250197496A1 (https=)
EP (1) EP4493593A1 (https=)
JP (1) JP2025509824A (https=)
KR (1) KR20250005568A (https=)
CN (1) CN119562970A (https=)
AU (1) AU2023236386A1 (https=)
CA (1) CA3254549A1 (https=)
IL (1) IL315714A (https=)
WO (1) WO2023178357A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL321437A (en) * 2022-12-14 2025-08-01 Evolveimmune Therapeutics Inc Bispecific antibody fusion molecules and methods for using them
WO2024173607A2 (en) 2023-02-14 2024-08-22 Evolveimmune Therapeutics, Inc. Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
WO2025064890A1 (en) 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
AU2024361727A1 (en) * 2023-10-16 2026-04-23 Evolveimmune Therapeutics, Inc. Combination therapies with ulbp2 targeting antibodies for treating cancers

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
ES2305886T3 (es) 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー/エス 二重特異性抗体の生産
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
CN102459591B (zh) 2009-05-20 2015-05-13 诺维莫尼公司 合成性的多肽文库以及用于建立具有天然多样性的多肽变体的方法
WO2011084255A2 (en) 2009-12-17 2011-07-14 Novimmune S.A. Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
KR101972446B1 (ko) 2011-05-27 2019-04-25 글락소 그룹 리미티드 Bcma(cd269/tnfrsf17)­결합 단백질
PT2768857T (pt) 2011-10-19 2020-01-27 Novimmune Sa Métodos para purificar anticorpos
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device
WO2016105450A2 (en) * 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
EP3916018A1 (en) 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
CN108290958B (zh) * 2015-10-02 2021-12-28 豪夫迈·罗氏有限公司 多特异性抗体
US20210163594A1 (en) * 2018-04-17 2021-06-03 Invenra Inc. Binding molecules
AU2019412561A1 (en) * 2018-12-24 2021-08-12 Sanofi Multispecific binding proteins with mutant Fab domains
EP3969119A1 (en) 2019-05-17 2022-03-23 Xencor, Inc. Il-7-fc-fusi0n proteins
CN115803057A (zh) 2020-04-29 2023-03-14 特纳奥尼公司 治疗多发性骨髓瘤的方法

Similar Documents

Publication Publication Date Title
JP2025509824A5 (https=)
CA2560305C (en) Human anti-epidermal growth factor receptor antibody
IL302078A (en) Anti-CCR8 monoclonal antibodies and their uses
JP2022515318A5 (https=)
JP2020510422A5 (https=)
JP2022093564A5 (https=)
JP2024527606A5 (https=)
JP2022545660A5 (https=)
IL317587A (en) Antibody against SIRPalpha
JP2022526764A5 (https=)
JP2021508469A5 (https=)
JP2020531043A5 (https=)
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
JP2018523493A5 (https=)
RU2018106452A (ru) Поливалетные и полиспецифичные gitr-связывающие слитые белки
JP2024531409A5 (https=)
JP2013527762A5 (https=)
JP2022512642A5 (https=)
US20240101675A1 (en) Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
JP2020502233A5 (https=)
JP2025507817A5 (https=)
JP2024538669A5 (https=)
JP2022526841A5 (https=)
CA3208455A1 (en) Novel anti-gremlin1 antibodies
JP2020505075A5 (https=)